1. Introduction {#sec1-jcm-07-00364}
===============

Lung cancer is one of the most fatal types of cancer, with 30% survival at one year post-diagnosis of non-small cell lung cancer \[[@B1-jcm-07-00364]\]. One way to improve the prognosis is to identify modifiable prognostic factors such as physical exercise, diet, or patient care. A major meta-analysis showed that psychological factors such as depression or coping predicted prognosis in cancer \[[@B2-jcm-07-00364]\]. However, physician empathy, i.e., the physician's ability to understand the affective and physical experiences of patients and convey this understanding to them \[[@B3-jcm-07-00364]\], was not part of this meta-analysis. Yet, in other conditions, physician empathy has been associated with multiple health outcomes such as HbA1C or cholesterol in diabetic patients for example \[[@B4-jcm-07-00364]\].

In oncology, associations between physician empathy and various patient outcomes have been shown \[[@B5-jcm-07-00364],[@B6-jcm-07-00364]\]. However, the role of patient perception of physician empathy in cancer survival has never been examined. The main objective of this study was thus to study the prognostic role of patient perception of physician empathy in cancer patient survival. Related to empathy, the role of social support in survival, including cancer survival, has been established \[[@B7-jcm-07-00364],[@B8-jcm-07-00364]\]. As a major source of support for cancer patients, physician empathy may impact survival \[[@B9-jcm-07-00364]\], perhaps especially in the context of informing patients on their disease progression. In such a personally meaningful context of receiving bad news, it is plausible that most patients attend carefully to the content and manner of the physician's speech. How physicians present the progress of the disease and its treatment to patients could play a major role in counteracting the potential helplessness/hopelessness of patients \[[@B10-jcm-07-00364]\], which are associated with poorer prognosis \[[@B11-jcm-07-00364],[@B12-jcm-07-00364]\]. Biologically, empathy is also related to the hormone oxytocin \[[@B13-jcm-07-00364]\], which has anti-proliferative, anti-metastatic and anti-angiogenic effects in some cancers \[[@B14-jcm-07-00364]\].

Furthermore, the effect of empathy on prognosis could vary according to the type of consultation (TC). For example, in an emotionally 'neutral' consultation (i.e., follow-up of treatment), physician empathy may have a weak effect on patients since patients are theoretically not distressed. Conversely, when bad news is being given, the effects of empathy could be stronger due to greater patient distress \[[@B15-jcm-07-00364],[@B16-jcm-07-00364]\]. Thus, we hypothesized that higher physician empathy would be related to a lower risk of death in bad news consultations but not in follow-up consultations (interaction hypothesis).

Finally, the definition of medical empathy is far from consensual \[[@B17-jcm-07-00364]\]. However, two types of empathy can be distinguished: a rather passive empathy of listening and compassion, whereby the physician listens attentively to patients and shows them compassion; and an active and positive empathy whereby the physician tries to give control and options to patients (e.g., providing a great deal of information and shared-decision making) and stays positive \[[@B18-jcm-07-00364]\]. We thus tested whether the hypothesized interaction between empathy and type of consultation, in relation to survival, was valid for both types of empathy or not (secondary objective). Multiple sociodemographic and medical confounders were taken into account. Two psychological confounders---patient cancer-related distress and patient emotional skills (i.e., patient skills in identifying, understanding, expressing and regulating emotions)---were also considered for their known role in cancer progression \[[@B2-jcm-07-00364],[@B19-jcm-07-00364],[@B20-jcm-07-00364],[@B21-jcm-07-00364],[@B22-jcm-07-00364],[@B23-jcm-07-00364]\], as they could modify the influence of empathy on survival.

2. Experimental Section {#sec2-jcm-07-00364}
=======================

2.1. Participants {#sec2dot1-jcm-07-00364}
-----------------

Inclusion criteria for physicians were treating thoracic cancer patients in an outpatient hospital setting. Inclusion criteria for patients were thoracic cancer at all stages or types of cancer, outpatients ≥18 years old, aware of the cancer diagnosis and with a Karnofsky Performance Status (KPS) ≥60. Performance status is a score that estimates the patient's ability to perform certain activities of daily living without the help of others. These daily activities include basic activities such as getting dressed, eating, and bathing, as well as more complex activities such as cleaning the house and working a regular job \[[@B24-jcm-07-00364]\]. The scores range from 0 "dead" to 100 "normal". For example, a patient at 60 requires occasional assistance and cares for most needs. Exclusion criteria were patients for whom there was no clear information regarding disease progression (e.g., waiting for test results) and those with a psychiatric disorder.

2.2. Design and Procedure {#sec2dot2-jcm-07-00364}
-------------------------

The data used were from an earlier study whose results had been reported previously \[[@B25-jcm-07-00364]\]. The study was approved by the French national ethics committee (approval number 14.545). In short, during the initial study, physicians working in the thoracic cancer department of the University of Lille (France) proposed the study to patients meeting the inclusion criteria at the end of a consultation. After the consultation, interested patients signed an informed consent and completed a questionnaire assessing their physician's empathy, their own cancer-related distress, emotional skills and socio-demographic data (see below for details). The type of consultation was reported by the physicians just after the consultations. Medical and clinical data---Karnofsky index, cancer stage, type of cancer, type of treatments before the study, Charlson index of comorbidities, metastases, mutations epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1, receptor tyrosine kinase (ROS), smoking status and time since diagnosis to study entry--were retrieved by the research assistants. The initial study ran from January 2015 to July 2016. For the present extended study, patients were followed until 1 April 2018, the date of censoring. At this point, research assistants added the survival status and treatments received by patients after the initial study.

2.3. Measures {#sec2dot3-jcm-07-00364}
-------------

Patient perception of physician empathy was measured using the Consultation and Relational Empathy (CARE) measure, a 10-item 5-point Likert scale \[[@B26-jcm-07-00364]\]. Items of this scale deal with the patient's perception of physician listening, respect, clear explanations and information provision, whether the physician fully understood his/her concerns, showed care and compassion, tried to be positive while staying honest, helped him/her to take control, and made an action plan with him/her. While the scale was designed to provide a global score, studies haves suggested that it could be divided into two subscales \[[@B18-jcm-07-00364],[@B26-jcm-07-00364],[@B27-jcm-07-00364]\]: a listening/compassion score (items 1 to 6) and an active/positive empathy score (items 7 to 10). Cronbach's α was 0.95 in our sample for the global score, 0.93 for the listening/compassion score, and 0.91 for the active/positive empathy score.

Cancer-related distress was assessed using the emotional dimension of the Functional Assessment of Cancer Therapy-General (FACT-G), a 6-item 5-point Likert scale \[[@B28-jcm-07-00364]\]. Higher scores represent higher distress. Examples of items are "I feel sad", "nervous", "I worry about dying", and "I am losing hope in the fight against my illness".

Patient emotional skills were assessed using the Short-Profile of Emotional Competence (S-PEC) scale \[[@B29-jcm-07-00364]\], a 20-item 5-point Likert scale providing a score of emotional skills (e.g., how patients identify, understand, express and regulate their emotions and the emotions of others in general). Examples of items are: "When I feel good, I can easily tell whether it is due to being proud of myself, happy or relaxed", "It is easy for me to explain my feelings to others" or "I find it difficult to handle my emotions" (reversed). Higher scores represent higher emotional skills.

The type of consultation was reported by the physician at the end of the consultation: if the patient was informed of a cancer progression in spite of treatment, or cancer relapse or the end of active treatment, this was considered a "bad news consultation". Otherwise, it was a "follow-up consultation".

Sociodemographic data were self-reported by patients and included age, gender, education and financial status.

Medical data were obtained from medical charts and included the Karnofsky index, cancer stage, type of cancer, Charlson index of comorbidities, metastases, mutation types (AGFR, ALK or ROS), treatments before and after the study entry, and time between diagnosis and study entry.

2.4. Statistical Analyses {#sec2dot4-jcm-07-00364}
-------------------------

Continuous variables are expressed as mean ± SD. Categorical variables are presented as absolute numbers and percentages. Distributions were examined for outliers. For categorical variables, frequencies were inspected and categories were merged when there were insufficient cases in one or more categories. Median follow-up was estimated using the inverse Kaplan-Meier method. Whether covariates differed between bad news and follow-up consultations was examined using independent sample *t* tests or Pearson χ². The univariate association of survival with each potential covariate was assessed using Cox proportional hazard regression models. From the fitted Cox models, the unadjusted hazard ratio with 95% CIs was obtained, and the significance of the association was tested using the Wald χ² statistic. Log-linearity and proportional hazards assumptions were checked for each covariate using Martingale and Schoenfeld residuals as well as supremum tests. If the proportional hazards assumption was not met, a piecewise model was created. The covariates that were tested included gender, age, education (no diploma, high school, bachelor degree vs. \> bachelor degree), financial situation (not comfortable, moderately comfortable vs. very comfortable), type and severity of cancer (Non-Small Cell Lung cancer (NSCL)-Small Cell Lung cancer (SCL) Stage I, II, III vs. NSCL-SCL stage IV, mesothelioma), metastases, Karnofsky index of 60--70 vs. \>70, time between diagnosis and inclusion in the study in years, Charlson index, mutation EGFR or ALK or ROS vs. none of these, cancer-related distress and patient emotional skills. All covariates except smoking status (too many missing data) and treatments (many treatments and high correlations with other medical data) were included in the multivariate model. Although no prior sample size calculation was done for this data analysis because of the retrospective design of this analysis, attention was paid to roughly respect the rule of 10 events per covariate \[[@B30-jcm-07-00364],[@B31-jcm-07-00364]\] in spite of debates about this rule of thumb \[[@B32-jcm-07-00364],[@B33-jcm-07-00364]\]. To choose between two non-nested models, the Schwarz Bayesian Criterion (SBC) was used, a smaller SBC indicating a better fit (at least two points of differences are required). To illustrate the effect of empathy on survival by the type of consultation with Kaplan-Meier curves, empathy was dichotomized at the median of 45. Curves were plotted, controlling for confounders, with continuous variables set at their means and categorical variables set at their mode. A two-tailed type I error rate \<0.05 was considered for statistical significance. Analyses and graphs were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-jcm-07-00364}
==========

3.1. Descriptive Statistics {#sec3dot1-jcm-07-00364}
---------------------------

Among the 179 patients in the total sample, the median follow-up was estimated at 3.1 years, 95% CI (2.92--3.09). Eighty-three patients (46.4%) were still alive at the time of censoring, 1 April, 2018 ([Table 1](#jcm-07-00364-t001){ref-type="table"}). Patients were mostly older men with a relatively low level of education, non-small cell lung cancers at stages I, II or III, a Karnofsky score indicating correct functional status. Forty three percent of patients were included in the study after the disclosure of bad news, consisting overwhelmingly of a change of treatment due to treatment failure. Five physicians participated in the study to present it to eligible patients and collect their agreements.

[Table A1](#jcm-07-00364-t0A1){ref-type="table"} ([Appendix A](#app1-jcm-07-00364){ref-type="app"}) shows the comparisons of the "bad news consultation" sample to the "follow-up consultation" one for all socio-demographic variables. Expected differences were observed between the two samples regarding the type and stages of cancer, the presence of metastases, the treatments received, the comorbidity index and the number of deaths at study censoring. At the psychological level, perceived empathy did not differ between bad news consultations and follow-up ones. Patients were also similar in emotional skills. As expected, however, cancer-related distress was higher after a bad news consultation than after a follow-up one.

[Table A2](#jcm-07-00364-t0A2){ref-type="table"} ([Appendix A](#app1-jcm-07-00364){ref-type="app"}) shows the comparisons of the low versus high patient-perceived physician empathy groups. The two groups were identical with the exception of three variables: there was a higher proportion of men in the low patient-reported empathy group compared to the other group (high empathy), cancer-related emotional distress was higher in the low empathy group, and patients had a lower level of emotional skills in the low empathy group.

3.2. Prediction of Survival with the General Score of Empathy {#sec3dot2-jcm-07-00364}
-------------------------------------------------------------

The univariate analyses ([Table 2](#jcm-07-00364-t002){ref-type="table"}) showed that age, comorbidities, cancer-related distress, stage IV cancers and mesotheliomas (compared to stages I, II, or III), metastasis and receiving chemotherapy before and/or after inclusion in the study were associated with an increased risk of death. Conversely, being a woman, having had surgery before the study, and being without additional treatment after inclusion in the study were protective factors for survival.

In the multivariate analysis ([Table 3](#jcm-07-00364-t003){ref-type="table"}), age, stage IV or mesothelioma, and cancer-related distress increased the risk of death. On the contrary, being a woman and having a high school diploma (compared to no diploma) were protective factors for survival. Controlling for sociodemographic and medical variables, the interaction between the type of consultation and patient-perceived empathy was significant (*p* = 0.02). However, it went in the opposite direction to our hypothesis. While, as hypothesized, empathy was not related to survival in follow-up consultation, HR = 0.96 by point of empathy score, 95% CI (0.90--1.03), it unexpectedly increased the risk of death by 6%, 95% CI (1.01--1.12) in bad news consultations ([Figure 1](#jcm-07-00364-f001){ref-type="fig"}). Thus, a one-point increase in the empathy questionnaire increased the risk of death by 6% in patients receiving bad news.

To be sure that treatments did not change the results, in an alternative model, we introduced treatments associated with survival at *p* \< 0.05 in the univariate analyses. This did not change the results, but the fit of this alternative model (SBC = 689.8) was not as good as that of the model presented in [Table 3](#jcm-07-00364-t003){ref-type="table"} (SBC = 668.8) and therefore it was not retained.

3.3. Prediction of Survival by Distinguishing the Two Types of Empathy {#sec3dot3-jcm-07-00364}
----------------------------------------------------------------------

In order to determine if the interaction was due to the two types of empathy, the model was reiterated identically but general empathy was first replaced by listening and compassion empathy (model A) and then by active and positive empathy (model B). The results are presented in [Table 4](#jcm-07-00364-t004){ref-type="table"}.

A significant interaction was found only with the empathy of listening and compassion. This type of empathy was associated with an increased risk of death in the bad news condition, HR = 1.13 by point of score, 95% CI (1.03--1.23), *p* = 0.008, but not in the follow-up condition, HR = 0.94 by point of score, 95% CI (0.86--1.05), *p* = 0.30. In contrast, active and positive empathy did not interact with the type of consultation, (*p* = 0.07). Regardless of the type of consultation, active/positive empathy was not associated with survival. Interestingly, both models detailing a specific type of empathy had a better fit (SBC of 556.3 for listening/compassion and 649.5 for active/positive empathy) than the model with general empathy (SBC of 668.8).

4. Discussion {#sec4-jcm-07-00364}
=============

To our knowledge, these are the first data examining the relationship between patients' perceived oncologist empathy and survival in lung cancer. Unexpectedly, in the bad news consultations, patient-perceived empathy was associated with a higher risk of death after controlling for sociodemographic, psychological and biomedical variables. It should be remembered that in our sample, mean perceived-empathy was high compared to other samples \[[@B34-jcm-07-00364]\]. In fact, a high level of physician empathy can worry patients and convey the message that the situation is really bad \[[@B35-jcm-07-00364]\], which could hasten death. Indeed, previous studies have shown that patient awareness of the palliative nature of the situation negatively impacts their survival \[[@B36-jcm-07-00364],[@B37-jcm-07-00364],[@B38-jcm-07-00364],[@B39-jcm-07-00364]\]. The fact that only compassion and listening empathy was associated with death is consistent with the hypothesis that highly unusual compassion and listening from physicians could be harmful, as it may equate to a loss of hope in patients' mind. On the contrary, positive and active empathy, which is by definition less worrying and more oriented towards an action plan, was not linked to survival status in our sample. Delivering bad news honestly while remaining positive and focused on an action plan is probably thus the challenge for physicians in order to maintain patient hope and control, as written in the American Society of Clinical Oncology guideline \[[@B40-jcm-07-00364]\]. The challenge is the same for patients: to maintain a feeling of hope and control in spite of bad news.

This study had limitations. First, the mean empathy was high so that our results need to be replicated in samples with lower empathy. Second, the generalizability of findings to other samples with different characteristics needs to be tested. In particular, our sample was mostly composed of male patients and the results may be totally different for female patients suffering from other cancers. Indeed, female cancer patients are much more sensitive to physician attitude, support, communication and information than male patients \[[@B41-jcm-07-00364]\]. Besides, in our sample, being a female patient was a protective factor. It might be the case because women are generally more prone to search and find social support, which is positively associated with higher survival \[[@B8-jcm-07-00364]\]. Our sample was also composed of a majority of people with a low level of education. High school diploma was a protective factor compared to patients with no diploma, probably as it allows a feeling of control and a better health literacy. A sample with a higher education level could have been less sensitive to physician empathy. Indeed, cancer patients with a high education are less sensitive to physician communication and attitude and rely more on alternate sources of information than patients with a low education level \[[@B41-jcm-07-00364],[@B42-jcm-07-00364]\]. The results could also be the opposite (as initially hypothesized) for cancers with a better prognosis. Finally, the results are limited by the exploratory nature of these post-hoc analyses and by the patient-reported measure of physician empathy. Further studies could consider more survival predictors such as immunohistochemistry biomarkers (e.g., p16 or BAP1 in pleural mesothelioma \[[@B43-jcm-07-00364]\]), risk profiles (i.e., a combination of risk factors, which predicts survival \[[@B44-jcm-07-00364]\]), or more specific treatments (e.g., PD-1 PD-L1). Taking into account these limitations, further evidence is essential to provide more definitive conclusions.

5. Conclusions {#sec5-jcm-07-00364}
==============

In bad news consultations, higher patient perception of physician listening and compassion empathy was associated with a higher risk of death in lung cancer patients. These results could have serious implications for physician-patient communication training as, if they were further confirmed, they would challenge the pervasive and implicit idea that physicians must always be compassionate and would call for a clarification of what is meant by 'empathy'. Research demonstrating weak or mixed evidence of the effectiveness of recommended guidelines for breaking bad news such as the six-step SPIKES protocol \[[@B42-jcm-07-00364],[@B45-jcm-07-00364],[@B46-jcm-07-00364]\], which promotes an empathic attitude, suggest that such "breaking-bad-news rules" do not meet all patients' needs \[[@B47-jcm-07-00364]\]. In fact, evidence-based research is really warranted regarding breaking bad news. Further research would then be necessary to elucidate what physician behaviors or words are related to the patient-perception of physician empathy, which in turn is related to better patient outcomes. Further research would also be needed to determine what patient factors (e.g., personality, medical history) might explain the patient-perception of physician empathy and patient outcomes.
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###### 

Characteristics of patients in follow-up versus bad news consultations.

  Characteristics                                           Follow-Up Consultations   Bad-News Consultations   *p* Value                               
  --------------------------------------------------------- ------------------------- ------------------------ ------------- ---- ------ ------------- ----------
  Patients (*n* = 179)                                                                                                                                 
  Sociodemographic data                                                                                                                                
  Age                                                                                                          63.4 (11.9)               63.4 (10.5)   0.99
  Men                                                       67                        66.3                                   54   69.2                 0.68
  Married or in a relationship (Yes)                        82                        81.2                                   53   69.7                 0.08
  Patient-reported education                                                                                                                           0.67
  No diploma                                                22                        21.8                                   17   21.8                 
  High school                                               49                        48.5                                   41   52.6                 
  Bachelor degree                                           18                        17.8                                   15   19.2                 
  More than bachelor degree                                 12                        11.9                                   5    6.4                  
  Patient-reported financial situation                                                                                                                 0.86
  Not at all or not very comfortable                        17                        16.8                                   11   14.1                 
  Moderately comfortable                                    55                        54.5                                   45   57.7                 
  Rather or very comfortable                                29                        28.7                                   22   28.2                 
  Medical data                                                                                                                                         
  Type and severity of cancer                                                                                                                          \<0.0001
  Stage I, II or III (NSCL or SCL)                          62                        61.4                                   22   28.2                 
  Stage IV (NSCL or SCL)                                    22                        21.8                                   34   43.6                 
  Mesothelioma (no stage assigned)                          8                         7.9                                    13   16.7                 
  Missing data                                              9                         8.9                                    9    11.5                 
  Smoker                                                                                                                                               0.12
  Never                                                     12                        11.9                                   12   15.4                 
  Ever                                                      71                        70.3                                   85   44.8                 
  Missing data                                              18                        17.8                                   31   39.7                 
  Time since diagnosis and inclusion in the study (years)                                                      2.5 (2.4)                 2.4 (1.9)     0.64
  Karnofsky index                                                                                                                                      0.76
  60--70                                                    5                         4.9                                    3    3.9                  
  \>70                                                      54                        93.1                                   71   91.0                 
  Missing data                                              2                         2.0                                    4    5.1                  
  Metastasis                                                17                        16.8                                   34   43.6                 \<0.0001
  Treatment before inclusion                                                                                                                           
  Chemotherapy                                              57                        56.4                                   62   79.5                 0.0012
  Surgery                                                   60                        59.4                                   22   28.2                 \<0.0001
  Radiotherapy                                              47                        46.5                                   24   30.8                 0.0325
  Targeted therapies                                        5                         5.1                                    9    11.7                 0.10
  Treatment after inclusion                                                                                                                            
  Surgery                                                   6                         5.9                                    2    2.6                  0.28
  Chemotherapy                                              31                        30.7                                   49   62.8                 \<0.0001
  Radiotherapy                                              16                        15.9                                   22   28.2                 0.04
  Targeted therapies                                        12                        11.9                                   19   24.4                 0.03
  Immunotherapy                                             11                        10.9                                   25   32.1                 0.0005
  No further treatment                                      49                        48.5                                   11   14.1                 \<0.0001
  Charlson index of comorbidities                                                                              7.6 (2.7)                 8.5 (2.2)     0.03
  Genetic mutation: EGFR or ALK or ROS (%)                  8                         7.9                                    12   15.4                 0.12
  Deceased at censoring                                     36                        35.6                                   52   66.7                 \<0.0001
  Psychological data                                                                                                                                   
  Cancer-related emotional distress                                                                            7.7 (5.5)                 9.6 (4.7)     0.02
  Patient emotional skills                                                                                     3.3 (0.6)                 3.3 (0.5)     0.66
  Patient-reported physician empathy                                                                           43.7 (6.7)                42.5 (7.1)    0.23

NSCL: Non-small cell lung cancer; SCL: Small cell lung cancer; EGFR: Epidermal Growth Factor Receptor; ALK: Anaplastic Lymphoma Kinase; ROS: ROS proto-oncogene 1, receptor tyrosine kinase.
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###### 

Characteristics of patients with low versus high patient-reported physician empathy (median split at 45).

  Characteristics                                           Low Patient-Reported Physician Empathy (≤45)   High Patient-Reported Physician Empathy (\>45)   *p* Value                               
  --------------------------------------------------------- ---------------------------------------------- ------------------------------------------------ ------------- ---- ------ ------------- -------
  Patients (*n* = 179)                                                                                                                                                                              
  Sociodemographic data                                                                                                                                                                             
  Age                                                                                                                                                       64.1 (12.4)               62.9 (10.3)   0.50
  Men                                                       67                                             74.4                                                           53   60.2                 0.04
  Married or in a relationship (Yes)                        64                                             72.7                                                           70   79.6                 0.29
  Education                                                                                                                                                                                         0.43
  No diploma                                                24                                             26.7                                                           15   17.1                 
  High school                                               44                                             48.9                                                           46   52.3                 
  Bachelor degree                                           15                                             16.7                                                           17   19.3                 
  More than bachelor degree                                 7                                              7.8                                                            10   11.4                 
  Financial ease                                                                                                                                                                                    0.09
  Not at all or not very comfortable                        13                                             14.4                                                           15   17.1                 
  Moderately comfortable                                    57                                             63.3                                                           42   47.7                 
  Rather or very comfortable                                20                                             22.2                                                           31   35.2                 
  Medical data                                                                                                                                                                                      
  Type and severity of cancer                                                                                                                                                                       0.71
  Stage I, II or III (NSCL or SCL)                          44                                             48.9                                                           40   45.5                 
  Stage IV (NSCL or SCL)                                    26                                             28.9                                                           29   33.0                 
  Mesothelioma (no stage assigned)                          12                                             13.3                                                           9    10.2                 
  Missing data                                              8                                              8.9                                                            10   11.4                 
  Smoker                                                                                                                                                                                            0.83
  Never                                                     12                                             13.3                                                           12   13.6                 
  Ever                                                      50                                             55.6                                                           55   62.5                 
  Missing data                                              28                                             31.1                                                           21   23.4                 
  Time since diagnosis and inclusion in the study (years)                                                                                                   2.3 (1.9)                 2.5 (2.3)     0.57
  Karnofsky index                                                                                                                                                                                   0.18
  60--70                                                    6                                              6.7                                                            2    2.3                  
  \>70                                                      83                                             92.2                                                           81   92.1                 
  Missing data                                              1                                              1.1                                                            5    5.7                  
  Metastasis                                                23                                             26.7                                                           27   31.0                 0.53
  Treatment before inclusion                                                                                                                                                                        
  Chemotherapy                                              57                                             63.3                                                           61   69.3                 0.40
  Surgery                                                   39                                             43.3                                                           43   48.9                 0.46
  Radiotherapy                                              36                                             40.0                                                           34   38.6                 0.85
  Targeted therapies                                        7                                              7.8                                                            7    8.1                  0.95
  Treatment after inclusion                                                                                                                                                                         
  Surgery                                                   4                                              4.4                                                            4    4.5                  0.97
  Chemotherapy                                              44                                             48.9                                                           35   39.8                 0.22
  Radiotherapy                                              23                                             25.6                                                           15   17.5                 0.17
  Targeted therapies                                        15                                             16.7                                                           16   18.2                 0.79
  Immunotherapy                                             19                                             21.1                                                           17   19.3                 0.77
  No further treatment                                      27                                             30.0                                                           33   37.5                 0.29
  Charlson index of comorbidities                                                                                                                           8.2 (2.5)                 7.7 (2.6)     0.29
  Genetic mutation: EGFR or ALK or ROS (%)                  10                                             11.1                                                           10   11.4                 0.12
  Deceased at censoring                                     45                                             50.6                                                           42   51.9                 0.87
  Psychological data                                                                                                                                                                                
  Cancer-related emotional distress                                                                                                                         9.7 (5.1)                 7.5 (5.1)     0.006
  Patient emotional skills                                                                                                                                  3.2 (0.4)                 3.5 (0.6)     0.005
  Patient-reported physician empathy                                                                                                                        37.1 (5.0)                48.6 (1.7)    0.001

NSCL: Non-small cell lung cancer; SCL: Small cell lung cancer; EGFR: Epidermal Growth Factor Receptor; ALK: Anaplastic Lymphoma Kinase; ROS: ROS proto-oncogene 1, receptor tyrosine kinase.

![Survival probability for patients with high perceived empathy (\>45) versus low empathy (≤ 45) by median split. (**a**) Follow-up consultations: adjusted Cox regressions showed no differences by empathy (*p* = 0.24); (**b**) Bad-news consultations: adjusted Cox regressions showed differences by empathy (*p* = 0.024).](jcm-07-00364-g001){#jcm-07-00364-f001}
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###### 

Descriptive statistics.

  Characteristics                                           Number of Patients   \%     Mean (Standard Deviation) (Range)
  --------------------------------------------------------- -------------------- ------ -----------------------------------
  Patients (*n* = 179)                                                                  
  Sociodemographic data                                                                 
  Age                                                                                   63.4 (11.3) (24--85)
  Men                                                       121                  67.6   
  In a relationship or married (Yes)                        135                  76.2   
  Patient-reported education                                                            
  No diploma                                                39                   21.8   
  High school                                               90                   50.3   
  Bachelor degree                                           33                   18.4   
  More than bachelor degree                                 17                   9.5    
  Patient-reported financial situation                                                  
  Not at all or not very comfortable                        28                   15.6   
  Moderately comfortable                                    100                  55.9   
  Rather or very comfortable                                51                   28.5   
  Medical data                                                                          
  Type of cancer                                                                        
  Non-small cell lung cancer (NSCL)                         135                  75.4   
  Small cell lung cancer (SCL)                              10                   5.6    
  Mesothelioma                                              21                   11.7   
  Missing data                                              13                   7.3    
  Cancer stage                                                                          
  Stage I, II or III (NSCL or SCL)                          84                   46.9   
  Stage IV (NSCL or SCL)                                    56                   31.3   
  Mesothelioma (no stage assigned)                          21                   11.7   
  Missing data                                              18                   10.1   
  Smoker                                                                                
  Never                                                     24                   13.4   
  Ever                                                      106                  59.2   
  Missing data                                              49                   27.4   
  Time since diagnosis and inclusion in the study (years)                               2.5 (2.2) (0.1--14.4)
  Karnofsky index                                                                       
  60--70                                                    8                    4.5    
  80                                                        20                   11.2   
  90                                                        56                   31.2   
  100                                                       89                   19.7   
  Missing data                                              6                    3.3    
  Metastasis                                                51                   28.5   
  Treatment before inclusion                                                            
  Surgery                                                   82                   45.9   
  Chemotherapy                                              119                  66.5   
  Radiotherapy                                              71                   39.7   
  Targeted therapies                                        14                   7.8    
  Treatment after inclusion                                                             
  Surgery                                                   8                    4.5    
  Chemotherapy                                              80                   44.7   
  Radiotherapy                                              38                   21.2   
  Targeted therapies                                        31                   17.3   
  Immunotherapy                                             36                   20.1   
  No further treatment                                      60                   33.5   
  Charlson index of comorbidities                                                       8.0 (2.6) (0--16)
  Genetic mutation: EGFR or ALK or ROS (%)                  20                   11.2   
  Type of consultation                                                                  
  Routine follow-up                                         100                  55.9   
  Bad news                                                  79                   43.0   
  Change of treatment because of treatment failure %        69                   38.6   
  Relapse or end of active treatment                        8                    4.5    
  Missing data                                              2                    1.1    
  Deceased at censorship                                                                
  Yes                                                       88                   49.2   
  No                                                        83                   46.4   
  Missing data                                              8                    4.4    
  Psychological data                                                                    
  Cancer-related emotional distress                                                     8.5 (5.2) (0--24)
  Patient emotional skills                                                              3.4 (0.5) (1.9--4.8)
  Patient-reported physician empathy                                                    43.2 (6.8) (22--50)
  Physicians (*n* = 5)                                                                  
  Age                                                                                   35.8 (5.85) (33--48)
  Men                                                                            50     

NSCL: Non-small cell lung cancer; SCL: Small cell lung cancer; EGFR: Epidermal Growth Factor Receptor; ALK: Anaplastic Lymphoma Kinase; ROS: Proto-oncogene tyrosine-protein kinase. ROS is an enzyme that in humans is encoded by the *ROS1* gene.
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###### 

Unadjusted Cox Proportional Hazard Ratios for overall survival.

  Variable                                                  HR     95% CI       *p* Value
  --------------------------------------------------------- ------ ------------ -----------
  Sociodemographic data                                                         
  Age                                                       1.02   1.01--1.04   0.015
  Woman                                                     0.51   0.30--0.84   0.009
  In a relationship or married (Yes)                        0.88   0.52--1.47   0.62
  Patient-reported Education                                                    
  Overall                                                                       0.49
  No diploma                                                1.97   0.79--4.92   0.15
  High school                                               1.47   0.63--3.46   0.37
  Bachelor degree                                           1.58   0.62--4.00   0.34
  More than bachelor degree (reference category)                                
  Patient-reported financial situation %                                        
  Overall                                                                       0.25
  Not at all or not very comfortable                        0.55   0.27--1.12   0.10
  Moderately comfortable                                    0.84   0.53--1.32   0.44
  Rather or very comfortable (reference category)                               
  Medical data                                                                  
  Type and severity of cancer                                                   \<0.0001
  Stage I, II or III (NSCL or SCL) (reference category)                         
  Stage IV (NSCL or SCL)                                    2.48   1.51--4.05   0.0003
  Mesothelioma (no stage assigned)                          3.36   1.81--6.23   0.0001
  Smoker (ever)                                             0.89   0.45--1.78   0.75
  Time since diagnosis and inclusion in the study (years)   0.96   0.87--1.07   0.46
  Karnofsky index (60--70 compared to higher)               2.11   0.92--4.85   0.08
  Metastasis %                                              1.63   1.04--2.56   0.03
  Treatment before inclusion %                                                  
  Chemotherapy                                              1.78   1.06--2.90   0.02
  Surgery                                                   0.34   0.21--0.54   \<0.0001
  Radiotherapy                                              0.95   0.62--1.45   0.80
  Targeted therapies                                        1.83   0.92--3.64   0.09
  Treatment after inclusion %                                                   
  Surgery                                                   0.17   0.02--1.25   0.08
  Chemotherapy                                              2.18   1.41--3.37   0.0005
  Radiotherapy                                              0.65   0.38--1.13   0.13
  Targeted therapies                                        1.56   0.95--2.54   0.08
  Immunotherapy                                             1.59   0.99--2.55   0.06
  No further treatment                                      0.48   0.29--0.81   0.006
  Charlson index of comorbidities                           1.19   1.09--1.31   \<0.0001
  Genetic mutation: EGFR or ALK or ROS (%)                  1.22   0.67--2.25   0.52
  Psychological data                                                            
  Cancer-related emotional distress                         1.05   1.01--1.09   0.01
  Patient emotional skills                                  0.87   0.59--1.29   0.48
  Patient-reported physician empathy                        0.99   0.97--1.03   0.87

NSCL: Non-small cell lung cancer; SCL: Small cell lung cancer; HR: hazard ratio; CI: confidence interval. EGFR: Epidermal Growth Factor Receptor; ALK: Anaplastic Lymphoma Kinase; ROS: ROS proto-oncogene 1, receptor tyrosine kinase.
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###### 

Adjusted Cox Proportional Hazard Model for overall survival.

  Variable                                                Hazard Ratio   95% CI       *p* Value
  ------------------------------------------------------- -------------- ------------ -----------
  Age                                                     1.04           1.00--1.07   0.029
  Woman                                                   0.48           0.26--0.89   0.019
  Patient-reported education                                                          
  No diploma (reference)                                                              
  High school                                             0.42           0.22--0.81   0.009
  Bachelor degree                                         0.41           0.16--1.06   0.07
  \>Bachelor                                              0.50           0.14--1.70   0.26
  Patient-reported financial situation                                                
  Not at all or not very comfortable (reference)                                      
  Moderately comfortable                                  1.42           0.58--3.45   0.44
  Rather or very comfortable                              1.27           0.46--3.57   0.65
  Type and severity of cancer                                                         
  Stage I, II or III (NSCL or SCL) (reference category)                               
  Stage IV (NSCL or SCL)                                  3.14           1.22--8.09   0.018
  Mesothelioma (no stage assigned)                        3.30           1.22--8.91   0.018
  Karnofsky index 60--70 (compared to \>70)               2.53           0.84--7.59   0.10
  Time since diagnosis and inclusion in the study         0.98           0.84--1.14   0.75
  Charlson index of comorbidities                         1.02           0.88--1.17   0.80
  Mutation (ALK, EGFR, ROS vs. none of them)              1.40           0.64--3.06   0.40
  Metastases                                              0.92           0.38--2.25   0.85
  Cancer-related emotional distress                       1.06           1.01--1.12   0.03
  Emotional skills                                        1.57           0.87--2.85   0.14
  Patient-reported physician empathy                      \-             \-           \-
  Type of consultation (bad news vs. follow-up)           \-             \-           \-
  Empathy \* type-of-consultation (interaction)                                       0.022
  Empathy in bad news consultations                       1.06           1.01--1.12   0.024
  Empathy in follow-up consultations                      0.96           0.90--1.03   0.24

NSCL: Non-small cell lung cancer; SCL: Small cell lung cancer; *n* = 143 (due to missing data in some variables), -2LL = 587.8, Akaike Information Criterion (AIC) = 625.8, Schwarz Bayesian Criterion (SBC) = 668.8. EGFR: Epidermal Growth Factor Receptor; ALK: Anaplastic Lymphoma Kinase; ROS: ROS proto-oncogene 1, receptor tyrosine kinase.
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###### 

Adjusted Cox Proportional Hazard Models for overall survival with specific types of empathy.

  Variable                                                             Hazard Ratio   95% CI       *p* Value
  -------------------------------------------------------------------- -------------- ------------ -----------
  Model A                                                                                          
  Compassion/listening empathy \* type-of-consultation (interaction)   \-             \-           0.016
  Compassion/listening in bad news consultations                       1.13           1.03--1.23   0.008
  Compassion/listening in follow-up consultations                      0.94           0.85--1.05   0.300
  Model B                                                                                          
  Active/positive empathy \* type-of-consultation (interaction)        \-             \-           0.07
  Active/positive in bad news consultations                            1.10           0.96--1.26   0.16
  Active/positive in follow-up consultations                           0.92           0.79--1.06   0.25

Covariates are not shown for readability purposes. Model A: -2LL = 575.6, Akaike Information Criterion (AIC) = 613.6, Schwarz Bayesian Criterion (SBC) = 556.3, *n* = 139; Model B: -2LL = 569.1, AIC = 607.1, SBC = 649.5, *n* = 138. CI: confidence interval.
